NCT06542588View on ClinicalTrials.gov

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

July 19, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Rectal Cancer
Interventions
COMBINATION_PRODUCT

HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody)

Short course radiotherapy sequential HLX07, Serplulimab and chemotherapy

Trial Locations (3)

430022

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Unknown

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER